Agreed ... but it is is far from common-sense to understand conceptually why in a P3 confirmatory trial you have a hierarchical structure of outcomes. And when the primary outcome fails statistical significance on your secondary outcomes is meaningless.
You would have to write a book to explain why this is so.
But on your second point about a terrible choice of outcomes … I would disagree agree slightly. The outcomes for CHF and LBP were not bad per se. Rather it was the process that generated them which was flawed. So I agree with dplanes point about overconfidence on weak P2 results.
The trouble is running P3 trials as if they were exploratory P2 trials – to learn as you go and to generate interesting sub-group efficacy signals on different endpoints for later testing in ……more P3 trials is completely un-viable.
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-290
-
- There are more pages in this discussion • 814 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
-0.015(1.51%) |
Mkt cap ! $1.124B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 97.5¢ | $603.7K | 611.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 70462 | 97.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 98.0¢ | 58370 | 30 |
View Market Depth
| Last trade - 11.19am 20/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |